drugset / Trial / NCT02676869
Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma
SequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, tolerability and recommended phase 2 dose of a new drug, known as IMP321, in combination with pembrolizumab when given to patients with unresectable or metastatic melanoma.
Timeline
- Start
- 2016-04
- Primary completion
- 2019-08
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMP321 | Protein / enzyme biologic | 1 mg | Subcutaneous |
| Subject | IMP321 | Protein / enzyme biologic | 6 mg | Subcutaneous |
| Subject | IMP321 | Protein / enzyme biologic | 30 mg | Subcutaneous |
| Background | Pembrolizumab | Monoclonal antibody | — | — |